|
| 36288506 | Focal Adhesion Kinase as a Therapeutic Target for Meningiomas With Somatic Neurofibromatosis Type 2 Mutations. | J Clin Oncol | 2023 |
| 35634744 | Bevacizumab for Cerebral Radionecrosis: A Single-Center Experience. | Can J Neurol Sci | 2023 |
| 35357288 | Trametinib for Painful Glomus Tumors in a Patient with Neurofibromatosis Type 1. | Can J Neurol Sci | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37272516 | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. | N Engl J Med | 2023 |
| 37268805 | BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets. | CNS Drugs | 2023 |
| 35275197 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. | Clin Cancer Res | 2022 |
| 35842871 | Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. | J Neurooncol | 2022 |
| 35601972 | First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide? | Neurooncol Pract | 2022 |
| 36970168 | Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival. | Neurooncol Pract | 2022 |
| 36420185 | Neurocognitive Performance in Adults Treated With Radiation for a Primary Brain Tumor. | Adv Radiat Oncol | 2022 |
| 36659968 | Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma. | Neurooncol Pract | 2022 |
| 36240081 | Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report. | Neurology | 2022 |
| 35932358 | Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. | J Neurooncol | 2022 |
| 35987165 | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. | ESMO Open | 2022 |
| 35098127 | Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial. | Neurooncol Adv | 2022 |
| 34980260 | Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. | Acta Neuropathol Commun | 2022 |
| 35312784 | Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. | Neuro Oncol | 2022 |
| 34000245 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. | Lancet Oncol | 2021 |
| 36988985 | Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. | Mov Disord Clin Pract | 2021 |
| 33795390 | Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. | Neurology | 2021 |
| 33740099 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. | Acta Neuropathol | 2021 |
| 33914057 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. | Neuro Oncol | 2021 |
| 34765975 | Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial. | Neurooncol Adv | 2021 |
| 34729484 | Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. | Neurooncol Adv | 2021 |
| 34548321 | First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. | Clin Cancer Res | 2021 |
| 34321130 | Neuro-Oncology Clinicians' Attitudes and Perspectives on Medical Assistance in Dying. | Can J Neurol Sci | 2021 |
| 32522302 | Glioblastoma Spinal Cord Metastasis With Short-Term Clinical Improvement After Radiation. | Can J Neurol Sci | 2020 |
| 31918786 | Molecular Classification of Diffuse Gliomas. | Can J Neurol Sci | 2020 |
| 31707687 | A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. | Invest New Drugs | 2020 |
| 33282325 | Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis. | Neurooncol Pract | 2020 |
| 33122230 | Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases. | BMJ Case Rep | 2020 |
| 32665311 | Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. | ESMO Open | 2020 |
| 32746640 | Proteasome inhibition for the treatment of glioblastoma. | Expert Opin Investig Drugs | 2020 |
| 32661186 | Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. | ESMO Open | 2020 |
| 32632894 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. | J Neurooncol | 2020 |
| 32895736 | Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. | Acta Neuropathol | 2020 |
| 32610225 | Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming. | J Neuroimmunol | 2020 |
| 30608896 | Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. | J Clin Oncol | 2019 |
| 29966463 | Significance of treatment response when managing patients with primary central nervous system lymphoma. | Leuk Lymphoma | 2019 |
| 31215634 | Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. | Neurosurgery | 2019 |
| 31548813 | <b><sup>18</sup></b> F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis. | Curr Oncol | 2019 |
| 30777876 | Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas. | Clin Cancer Res | 2019 |
| 30847839 | Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial. | J Neurooncol | 2019 |
| 30266892 | A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. | Oncologist | 2019 |
| 29016943 | Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. | Neuro Oncol | 2018 |
| 30153289 | ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. | PLoS One | 2018 |
| 29897562 | Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. | Neuro Oncol | 2018 |
| 29608764 | mTOR inhibition in glioblastoma: requiem for a dream? | Neuro Oncol | 2018 |
| 29571083 | Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. | Eur J Cancer | 2018 |